MedTrace Logo

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

NCT03104595 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-08-15

No results posted yet for this study

Summary

To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.

Conditions

Interventions

DRUG

EC-18

oral administration

Sponsors & Collaborators

  • Enzychem Lifesciences Corporation

    lead INDUSTRY

Principal Investigators

  • Sung-Bae Kim, MD, PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2019-11-26
Completion
2019-12-05
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03104595 on ClinicalTrials.gov